Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 17/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9996065 | 0.84 | CYP17A1 (0.78) | CYP17A1CYP19A1 | |
| SCHEMBL9784379 | 0.84 | CYP19A1 (0.66) | CYP17A1CYP19A1 | |
| SCHEMBL2348613 | 0.82 | CYP17A1 (0.67) | CYP17A1CYP19A1 | |
| SCHEMBL9784394 | 0.82 | CYP17A1 (0.67) | CYP17A1CYP19A1 | |
| SCHEMBL9784361 | 0.80 | CYP17A1 (0.64) | CYP17A1CYP19A1 | |
| SCHEMBL9791445 | 0.80 | CYP17A1 (0.71) | CYP17A1 | |
| SCHEMBL10520031 | 0.79 | CYP17A1 (0.66) | CYP17A1CYP19A1 | |
| SCHEMBL9784415 | 0.79 | CYP17A1 (0.70) | CYP17A1CYP19A1 | |
| SCHEMBL4578052 | 0.79 | CYP17A1 (0.83) | CYP17A1CYP19A1 | |
| SCHEMBL9784380 | 0.78 | CYP17A1 (0.68) | CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0340153-A1 | N-substituted imidazoles, process for their preparation and their use in medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-11-02 | — | — | EP | claimed |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | UNIVERSITY OF MASSACHUSETTS (US) | 2026-03-31 | — | — | US | disclosed |
| US-20210109085-A1 | METHODS FOR PREDICTING ER-MEDIATED DNA DAMAGE | UNIVERSITY OF MASSACHUSETTS | 2021-04-15 | — | — | US | disclosed |
| US-8871750-B2 | Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus | WAYNE STATE UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8008333-B2 | Inducing ovulation; increasing response to follicle stimulating hormone | ARES TRADING S.A. (CH) | 2011-08-30 | — | — | US | disclosed |
| US-7846957-B2 | Aromatase inhibition to enhance assisted reproduction | ARES TRADING S.A. (CH) | 2010-12-07 | — | — | US | disclosed |
| US-7820706-B2 | Multiple dose aromatase inhibitor for treating infertility | ARES TRADING S.A. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CASPER ROBERT F | 2010-04-29 | — | — | US | disclosed |
| EP-1898923-A4 | AROMATASE INHIBITORS FOR EMERGENCY CONTRACEPTION | CASPER ROBERT F (CA) | 2009-05-20 | — | — | EP | disclosed |
| EP-1804805-A4 | USE OF AROMATASE INHIBITORS FOR THE TREATMENT OF ECTOPIC PREGNANCY | UNIV WAYNE STATE (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1383578-A1 | SINGLE DOSE AROMATASE INHIBITOR FOR TREATING INFERTILITY | ARES TRADING S.A. (CH) | 2004-01-28 | — | — | EP | disclosed |
| EP-1381431-A1 | AROMATASE INHIBITION TO ENHANCE ASSISTED REPRODUCTION | ARES TRADING S.A. (CH) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003082336-A1 | FEMALE BIRTH CONTROL METHOD | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082299-A1 | IMPROVED HORMONE REPLACEMENT THERAPY | JENCAP RESEARCH LTD. (CA) | 2003-10-09 | — | — | WO | disclosed |
| WO-2002083146-A1 | MULTIPLE DOSE AROMATASE INHIBITOR FOR TREATING INFERTILITY | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083241-A1 | SINGLE DOSE AROMATASE INHIBITOR FOR TREATING INFERTILITY | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083240-A1 | AROMATASE INHIBITION TO ENHANCE ASSISTED REPRODUCTION | ARES TRADING S.A. (CH) | 2002-10-24 | — | — | WO | disclosed |
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | disclosed |
| US-5045558-A | Aromatase inhibitors, prevention of estrogen biosynthesis, treatment of breast cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-09-03 | — | — | US | disclosed |
| EP-0340153-A1 | N-substituted imidazoles, process for their preparation and their use in medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105640-A1 | Aromatase Inhibitors for Emergency Contraception | CYP19A1, SHBG, HSD17B11 | CYP17A1 4/4885CYP19A1 1/4885 |
| US-12590950-B2 | Methods for predicting ER-mediated DNA damage | ESR1, ESR2, ESRRA | CYP17A1 268/4885CYP19A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.